See more : Beautiful China Holdings Company Limited (0706.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shenzhen Weiguang Biological Products Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PFA Invest Indeks Mellemlange O (PFIIMO.CO) Income Statement Analysis – Financial Results
- BlackRock Energy and Resources Income Trust plc (BERI.L) Income Statement Analysis – Financial Results
- Guangzhou Kingteller Technology Co.,Ltd. (002177.SZ) Income Statement Analysis – Financial Results
- Globalink Investment Inc. (GLLIR) Income Statement Analysis – Financial Results
- Langold Real Estate Co., Ltd. (002305.SZ) Income Statement Analysis – Financial Results
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ)
About Shenzhen Weiguang Biological Products Co., Ltd.
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human albumin, intravenous immunoglobulin (pH4), freeze-dried intravenous human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies patient immunoglobulin, tetanus human immunoglobulin, histamine human immunoglobulin, and human fibrinogen, as well as a total of 9 varieties and 21 specifications. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.05B | 667.93M | 907.43M | 904.56M | 821.47M | 687.95M | 623.39M | 566.14M | 500.94M | 452.77M | 355.21M | 300.07M |
Cost of Revenue | 615.26M | 427.02M | 536.52M | 568.22M | 506.13M | 414.33M | 347.17M | 297.84M | 268.01M | 252.03M | 179.89M | 155.00M |
Gross Profit | 433.24M | 240.91M | 370.91M | 336.35M | 315.34M | 273.62M | 276.21M | 268.30M | 232.94M | 200.75M | 175.32M | 145.07M |
Gross Profit Ratio | 41.32% | 36.07% | 40.87% | 37.18% | 38.39% | 39.77% | 44.31% | 47.39% | 46.50% | 44.34% | 49.36% | 48.35% |
Research & Development | 55.77M | 35.87M | 47.59M | 45.10M | 40.16M | 23.70M | 25.63M | 24.77M | 19.78M | 13.78M | 15.47M | 11.94M |
General & Administrative | 24.68M | 18.02M | 21.17M | 28.00M | 24.70M | 18.05M | 18.72M | 17.11M | 13.99M | 12.11M | 47.30M | 42.99M |
Selling & Marketing | 40.88M | 27.25M | 23.78M | 19.69M | 24.02M | 24.01M | 14.35M | 12.84M | 12.16M | 11.30M | 11.92M | 11.40M |
SG&A | 65.57M | 45.27M | 44.95M | 47.69M | 48.72M | 42.07M | 33.07M | 29.95M | 26.15M | 23.41M | 59.23M | 54.39M |
Other Expenses | 66.13M | 42.60M | 41.33M | 31.55M | 24.44M | 1.35M | 10.50M | 28.33M | 31.10M | 31.39M | 11.00M | 4.45M |
Operating Expenses | 185.94M | 123.74M | 133.87M | 124.33M | 113.32M | 88.04M | 83.72M | 82.33M | 69.61M | 59.08M | 62.51M | 58.54M |
Cost & Expenses | 801.19M | 550.76M | 670.39M | 692.55M | 619.46M | 502.37M | 430.89M | 380.17M | 337.62M | 311.11M | 242.40M | 213.54M |
Interest Income | 2.82M | 4.49M | 8.91M | 8.36M | 1.54M | 2.38M | 4.43M | 771.59K | 695.51K | 469.63K | 19.56M | 7.49M |
Interest Expense | 15.31M | 2.06M | 2.77M | 1.06M | 399.68K | 3.75M | 12.89M | 18.06M | 24.77M | 24.83M | 0.00 | 0.00 |
Depreciation & Amortization | 89.44M | 66.84M | 57.24M | 46.47M | 39.79M | 41.83M | 41.59M | 40.08M | 40.07M | 39.18M | 29.72M | 15.72M |
EBITDA | 350.21M | 207.18M | 301.47M | 266.70M | 238.64M | 227.55M | 232.47M | 237.68M | 210.49M | 181.86M | 142.53M | 102.24M |
EBITDA Ratio | 33.40% | 28.37% | 33.12% | 29.23% | 29.50% | 33.35% | 38.56% | 41.99% | 42.10% | 41.52% | 40.15% | 34.17% |
Operating Income | 247.31M | 138.17M | 241.74M | 220.64M | 199.14M | 182.00M | 178.84M | 168.56M | 139.09M | 111.11M | 93.17M | 79.17M |
Operating Income Ratio | 23.59% | 20.69% | 26.64% | 24.39% | 24.24% | 26.46% | 28.69% | 29.77% | 27.77% | 24.54% | 26.23% | 26.38% |
Total Other Income/Expenses | -1.85M | -849.88K | -566.44K | -1.60M | -850.44K | -177.43K | 1.95M | -6.43M | -17.63M | -17.73M | -8.56M | -3.45M |
Income Before Tax | 245.45M | 137.32M | 241.17M | 219.04M | 198.29M | 181.82M | 180.78M | 179.48M | 145.65M | 117.85M | 104.17M | 83.21M |
Income Before Tax Ratio | 23.41% | 20.56% | 26.58% | 24.22% | 24.14% | 26.43% | 29.00% | 31.70% | 29.07% | 26.03% | 29.33% | 27.73% |
Income Tax Expense | 27.91M | 16.20M | 36.18M | 29.46M | 27.14M | 25.19M | 26.03M | 26.25M | 20.79M | 17.31M | 15.29M | 11.76M |
Net Income | 218.65M | 117.52M | 205.44M | 190.40M | 171.34M | 156.64M | 154.75M | 153.23M | 124.86M | 100.54M | 88.88M | 71.45M |
Net Income Ratio | 20.85% | 17.59% | 22.64% | 21.05% | 20.86% | 22.77% | 24.82% | 27.07% | 24.92% | 22.21% | 25.02% | 23.81% |
EPS | 0.96 | 0.52 | 0.91 | 0.84 | 0.76 | 0.69 | 0.78 | 0.90 | 0.73 | 0.59 | 0.52 | 0.42 |
EPS Diluted | 0.96 | 0.52 | 0.91 | 0.84 | 0.76 | 0.69 | 0.78 | 0.90 | 0.73 | 0.59 | 0.52 | 0.42 |
Weighted Avg Shares Out | 226.80M | 226.80M | 226.80M | 226.80M | 226.80M | 226.80M | 198.14M | 170.25M | 170.26M | 170.27M | 169.68M | 170.49M |
Weighted Avg Shares Out (Dil) | 226.80M | 226.80M | 226.80M | 226.80M | 226.80M | 226.81M | 198.15M | 170.25M | 170.26M | 170.27M | 169.68M | 170.49M |
Source: https://incomestatements.info
Category: Stock Reports